Management of hyperlipidemia in children with refractory nephrotic syndrome: The effect of statin therapy
The efficacy and safety of hydroxymethylglutaric coenzyme A reductase inhibitor (statins) in the treatment of hyperlipidemia were evaluated in 12 infants and children with steroid-resistant nephrotic syndrome followed prospectively for 1 to 5 years. All patients experienced a hypolipidemic response...
Gespeichert in:
| Veröffentlicht in: | The Journal of pediatrics 1997-03, Vol.130 (3), p.470-474 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 474 |
|---|---|
| container_issue | 3 |
| container_start_page | 470 |
| container_title | The Journal of pediatrics |
| container_volume | 130 |
| creator | Sanjad, Sami A. Al-Abbad, Abbas Al-Shorafa, Saleh |
| description | The efficacy and safety of hydroxymethylglutaric coenzyme A reductase inhibitor (statins) in the treatment of hyperlipidemia were evaluated in 12 infants and children with steroid-resistant nephrotic syndrome followed prospectively for 1 to 5 years. All patients experienced a hypolipidemic response with a marked reduction in their total cholesterol (40%), low-density lipoprotein cholesterol (44%), and triglyceride levels (33%), but no appreciable change in high-density lipoprotein cholesterol. Statin therapy was well tolerated without clinical or laboratory adverse effects. In spite of a significant hypolipidemic response to statin therapy there were no changes observed in the degree of proteinuria, hypoalbuminemia, or in the rate of progression to chronic renal failure. Long-term controlled studies with statin therapy are needed to further document or negate their renoprotective role in refractory nephrotic syndrome. |
| doi_str_mv | 10.1016/S0022-3476(97)70213-0 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_78864235</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0022347697702130</els_id><sourcerecordid>78864235</sourcerecordid><originalsourceid>FETCH-LOGICAL-c389t-c33e384d9e3482e2d1a01216065610bc817f1fb670961f9351f45580d5728f7e3</originalsourceid><addsrcrecordid>eNqFkD1vFDEQhi0ECpfAT4jkAiEoloztXXtNg1BEIFIiCkJt-bxj1mi_sH1B--9x7k7X0oyLeead8UPIJYMPDJi8-gHAeSVqJd9p9V4BZ6KCZ2TDQKtKtkI8J5sT8pKcp_QbAHQNcEbONEhRc7Uh4d5O9heOOGU6e9qvC8YhLKHDMVgaJur6MHQRJ_o35J5G9NG6PMeVTrj0cc7B0bROXZxH_EgfeqToPbp9WMo2l4TcY7TL-oq88HZI-Pr4XpCfN18err9Vd9-_3l5_vqucaHUuVaBo606jqFuOvGMWGGcSZCMZbF3LlGd-KxVoybwWDfN107TQNYq3XqG4IG8PuUuc_-wwZTOG5HAY7ITzLhnVtrLmoilgcwBdnFMqPzNLDKONq2FgnhSbvWLz5M9oZfaKDZS5y-OC3XbE7jR1dFr6b459m5wdirDJhXTCuAStG12wTwcMi4zHgNEkF3By2IVYBJpuDv855B99z5gi</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>78864235</pqid></control><display><type>article</type><title>Management of hyperlipidemia in children with refractory nephrotic syndrome: The effect of statin therapy</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Sanjad, Sami A. ; Al-Abbad, Abbas ; Al-Shorafa, Saleh</creator><creatorcontrib>Sanjad, Sami A. ; Al-Abbad, Abbas ; Al-Shorafa, Saleh</creatorcontrib><description>The efficacy and safety of hydroxymethylglutaric coenzyme A reductase inhibitor (statins) in the treatment of hyperlipidemia were evaluated in 12 infants and children with steroid-resistant nephrotic syndrome followed prospectively for 1 to 5 years. All patients experienced a hypolipidemic response with a marked reduction in their total cholesterol (40%), low-density lipoprotein cholesterol (44%), and triglyceride levels (33%), but no appreciable change in high-density lipoprotein cholesterol. Statin therapy was well tolerated without clinical or laboratory adverse effects. In spite of a significant hypolipidemic response to statin therapy there were no changes observed in the degree of proteinuria, hypoalbuminemia, or in the rate of progression to chronic renal failure. Long-term controlled studies with statin therapy are needed to further document or negate their renoprotective role in refractory nephrotic syndrome.</description><identifier>ISSN: 0022-3476</identifier><identifier>EISSN: 1097-6833</identifier><identifier>DOI: 10.1016/S0022-3476(97)70213-0</identifier><identifier>PMID: 9063427</identifier><identifier>CODEN: JOPDAB</identifier><language>eng</language><publisher>New York, NY: Mosby, Inc</publisher><subject>Biological and medical sciences ; Child ; Child, Preschool ; Female ; General and cellular metabolism. Vitamins ; Humans ; Hydroxymethylglutaryl CoA Reductases ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use ; Hyperlipidemias - drug therapy ; Hyperlipidemias - etiology ; Hypolipidemic Agents - therapeutic use ; Infant ; Lipids - blood ; Male ; Medical sciences ; Nephrotic Syndrome - complications ; Nephrotic Syndrome - drug therapy ; Pharmacology. Drug treatments ; Proteins - therapeutic use ; Treatment Outcome</subject><ispartof>The Journal of pediatrics, 1997-03, Vol.130 (3), p.470-474</ispartof><rights>1997 Mosby, Inc.</rights><rights>1997 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c389t-c33e384d9e3482e2d1a01216065610bc817f1fb670961f9351f45580d5728f7e3</citedby><cites>FETCH-LOGICAL-c389t-c33e384d9e3482e2d1a01216065610bc817f1fb670961f9351f45580d5728f7e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0022347697702130$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,65309</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2609959$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9063427$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sanjad, Sami A.</creatorcontrib><creatorcontrib>Al-Abbad, Abbas</creatorcontrib><creatorcontrib>Al-Shorafa, Saleh</creatorcontrib><title>Management of hyperlipidemia in children with refractory nephrotic syndrome: The effect of statin therapy</title><title>The Journal of pediatrics</title><addtitle>J Pediatr</addtitle><description>The efficacy and safety of hydroxymethylglutaric coenzyme A reductase inhibitor (statins) in the treatment of hyperlipidemia were evaluated in 12 infants and children with steroid-resistant nephrotic syndrome followed prospectively for 1 to 5 years. All patients experienced a hypolipidemic response with a marked reduction in their total cholesterol (40%), low-density lipoprotein cholesterol (44%), and triglyceride levels (33%), but no appreciable change in high-density lipoprotein cholesterol. Statin therapy was well tolerated without clinical or laboratory adverse effects. In spite of a significant hypolipidemic response to statin therapy there were no changes observed in the degree of proteinuria, hypoalbuminemia, or in the rate of progression to chronic renal failure. Long-term controlled studies with statin therapy are needed to further document or negate their renoprotective role in refractory nephrotic syndrome.</description><subject>Biological and medical sciences</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Female</subject><subject>General and cellular metabolism. Vitamins</subject><subject>Humans</subject><subject>Hydroxymethylglutaryl CoA Reductases</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use</subject><subject>Hyperlipidemias - drug therapy</subject><subject>Hyperlipidemias - etiology</subject><subject>Hypolipidemic Agents - therapeutic use</subject><subject>Infant</subject><subject>Lipids - blood</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Nephrotic Syndrome - complications</subject><subject>Nephrotic Syndrome - drug therapy</subject><subject>Pharmacology. Drug treatments</subject><subject>Proteins - therapeutic use</subject><subject>Treatment Outcome</subject><issn>0022-3476</issn><issn>1097-6833</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkD1vFDEQhi0ECpfAT4jkAiEoloztXXtNg1BEIFIiCkJt-bxj1mi_sH1B--9x7k7X0oyLeead8UPIJYMPDJi8-gHAeSVqJd9p9V4BZ6KCZ2TDQKtKtkI8J5sT8pKcp_QbAHQNcEbONEhRc7Uh4d5O9heOOGU6e9qvC8YhLKHDMVgaJur6MHQRJ_o35J5G9NG6PMeVTrj0cc7B0bROXZxH_EgfeqToPbp9WMo2l4TcY7TL-oq88HZI-Pr4XpCfN18err9Vd9-_3l5_vqucaHUuVaBo606jqFuOvGMWGGcSZCMZbF3LlGd-KxVoybwWDfN107TQNYq3XqG4IG8PuUuc_-wwZTOG5HAY7ITzLhnVtrLmoilgcwBdnFMqPzNLDKONq2FgnhSbvWLz5M9oZfaKDZS5y-OC3XbE7jR1dFr6b459m5wdirDJhXTCuAStG12wTwcMi4zHgNEkF3By2IVYBJpuDv855B99z5gi</recordid><startdate>19970301</startdate><enddate>19970301</enddate><creator>Sanjad, Sami A.</creator><creator>Al-Abbad, Abbas</creator><creator>Al-Shorafa, Saleh</creator><general>Mosby, Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19970301</creationdate><title>Management of hyperlipidemia in children with refractory nephrotic syndrome: The effect of statin therapy</title><author>Sanjad, Sami A. ; Al-Abbad, Abbas ; Al-Shorafa, Saleh</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c389t-c33e384d9e3482e2d1a01216065610bc817f1fb670961f9351f45580d5728f7e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>Biological and medical sciences</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Female</topic><topic>General and cellular metabolism. Vitamins</topic><topic>Humans</topic><topic>Hydroxymethylglutaryl CoA Reductases</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use</topic><topic>Hyperlipidemias - drug therapy</topic><topic>Hyperlipidemias - etiology</topic><topic>Hypolipidemic Agents - therapeutic use</topic><topic>Infant</topic><topic>Lipids - blood</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Nephrotic Syndrome - complications</topic><topic>Nephrotic Syndrome - drug therapy</topic><topic>Pharmacology. Drug treatments</topic><topic>Proteins - therapeutic use</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sanjad, Sami A.</creatorcontrib><creatorcontrib>Al-Abbad, Abbas</creatorcontrib><creatorcontrib>Al-Shorafa, Saleh</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The Journal of pediatrics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sanjad, Sami A.</au><au>Al-Abbad, Abbas</au><au>Al-Shorafa, Saleh</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Management of hyperlipidemia in children with refractory nephrotic syndrome: The effect of statin therapy</atitle><jtitle>The Journal of pediatrics</jtitle><addtitle>J Pediatr</addtitle><date>1997-03-01</date><risdate>1997</risdate><volume>130</volume><issue>3</issue><spage>470</spage><epage>474</epage><pages>470-474</pages><issn>0022-3476</issn><eissn>1097-6833</eissn><coden>JOPDAB</coden><abstract>The efficacy and safety of hydroxymethylglutaric coenzyme A reductase inhibitor (statins) in the treatment of hyperlipidemia were evaluated in 12 infants and children with steroid-resistant nephrotic syndrome followed prospectively for 1 to 5 years. All patients experienced a hypolipidemic response with a marked reduction in their total cholesterol (40%), low-density lipoprotein cholesterol (44%), and triglyceride levels (33%), but no appreciable change in high-density lipoprotein cholesterol. Statin therapy was well tolerated without clinical or laboratory adverse effects. In spite of a significant hypolipidemic response to statin therapy there were no changes observed in the degree of proteinuria, hypoalbuminemia, or in the rate of progression to chronic renal failure. Long-term controlled studies with statin therapy are needed to further document or negate their renoprotective role in refractory nephrotic syndrome.</abstract><cop>New York, NY</cop><pub>Mosby, Inc</pub><pmid>9063427</pmid><doi>10.1016/S0022-3476(97)70213-0</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0022-3476 |
| ispartof | The Journal of pediatrics, 1997-03, Vol.130 (3), p.470-474 |
| issn | 0022-3476 1097-6833 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_78864235 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Biological and medical sciences Child Child, Preschool Female General and cellular metabolism. Vitamins Humans Hydroxymethylglutaryl CoA Reductases Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use Hyperlipidemias - drug therapy Hyperlipidemias - etiology Hypolipidemic Agents - therapeutic use Infant Lipids - blood Male Medical sciences Nephrotic Syndrome - complications Nephrotic Syndrome - drug therapy Pharmacology. Drug treatments Proteins - therapeutic use Treatment Outcome |
| title | Management of hyperlipidemia in children with refractory nephrotic syndrome: The effect of statin therapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T06%3A05%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Management%20of%20hyperlipidemia%20in%20children%20with%20refractory%20nephrotic%20syndrome:%20The%20effect%20of%20statin%20therapy&rft.jtitle=The%20Journal%20of%20pediatrics&rft.au=Sanjad,%20Sami%20A.&rft.date=1997-03-01&rft.volume=130&rft.issue=3&rft.spage=470&rft.epage=474&rft.pages=470-474&rft.issn=0022-3476&rft.eissn=1097-6833&rft.coden=JOPDAB&rft_id=info:doi/10.1016/S0022-3476(97)70213-0&rft_dat=%3Cproquest_cross%3E78864235%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=78864235&rft_id=info:pmid/9063427&rft_els_id=S0022347697702130&rfr_iscdi=true |